Welcome to our dedicated page for Spruce Biosciences news (Ticker: SPRB), a resource for investors and traders seeking the latest updates and insights on Spruce Biosciences stock.
Spruce Biosciences, Inc. (SPRB) is a clinical-stage biopharmaceutical company pioneering non-steroidal therapies for rare endocrine disorders. This page serves as the definitive source for verified news and developments surrounding SPRB's innovative research and clinical programs.
Investors and medical professionals will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated content includes updates on SPRB's lead candidate tildacerfont for congenital adrenal hyperplasia (CAH), financial disclosures, and scientific conference presentations.
Key information categories include:
- Clinical trial phase updates
- Regulatory agency communications
- Peer-reviewed research publications
- Strategic industry collaborations
- Financial performance summaries
Bookmark this page for direct access to SPRB's official announcements, maintaining informed perspectives on therapeutic advancements in endocrine care.
Spruce Biosciences (NASDAQ: SPRB), a late-stage biopharmaceutical company, announced its participation in two virtual investor conferences in March 2022. The Cowen 42nd Annual Health Care Conference will occur from March 7-9, featuring a company presentation on March 9 at 11:10 a.m. ET. The Oppenheimer 32nd Annual Healthcare Conference will take place from March 15-17, with a fireside chat on March 16 at 8:00 a.m. ET. Webcasts of these events will be accessible on the company's investor relations website.
Spruce Biosciences, Inc. (NASDAQ: SPRB) announces participation in the SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022, at 5:00 PM EST. CEO Javier Szwarcberg and CFO Samir Gharib will engage in a virtual fireside chat. This company focuses on developing therapies for rare endocrine disorders, particularly its candidate tildacerfont for classic congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS). Interested parties can access the live webcast on the company's investor relations website, with an archived replay available for 30 days.
Spruce Biosciences, Inc. (NASDAQ: SPRB) announced updates on its CAHmelia clinical program for tildacerfont, targeting adult classic congenital adrenal hyperplasia. The company plans to expand its global trial sites by up to 50, enhancing recruitment and optimizing study design for CAHmelia-203 and CAHmelia-204. Strategic prioritization extends its cash runway into Q2 2024, with topline data expected in 2H 2023 and 2H 2024 respectively. Additionally, a Phase 2 trial for pediatric CAH has been initiated, while a PCOS program is also underway.
Spruce Biosciences has appointed Dr. Javier Szwarcberg as CEO and promoted Samir Gharib to President, who will also remain CFO. Dr. Szwarcberg brings over 18 years of experience, having led 22 clinical trials and achieved 4 drug approvals. His focus will be on advancing tildacerfont, a potential first non-steroidal therapy for classic congenital adrenal hyperplasia (CAH). Gharib's promotion aims to leverage his business acumen for the company’s growth. Szwarcberg will receive stock options as part of his inducement award.
Spruce Biosciences, a late-stage biopharmaceutical company, announced that CFO Samir Gharib will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. A pre-recorded presentation will be available on-demand starting November 22, 2021, at 10:00 AM EST on the company's investor relations website. Spruce focuses on developing therapies for rare endocrine disorders, including the potential first non-steroidal treatment for classic congenital adrenal hyperplasia and polycystic ovary syndrome.
Spruce Biosciences, Inc. (Nasdaq: SPRB) announced plans to initiate Phase 2 trials for pediatric classic congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS). The adult CAHmelia program has been expanded to Australia and Canada to enhance patient recruitment. Financially, as of September 30, 2021, the company reported $131.3 million in cash and investments. However, R&D expenses increased to $8.6 million in Q3 2021, reflecting ongoing development costs, and the net loss rose to $11.4 million.
Spruce Biosciences, Inc. (NASDAQ: SPRB) has appointed Mike Grey as interim CEO, effective immediately, succeeding Richard King, who is retiring. Grey, the Executive Chairman, emphasized the company's commitment to advancing tildacerfont for treating classic congenital adrenal hyperplasia (CAH), a significant unmet need in rare endocrine disorders. The clinical program is expanding, with upcoming Phase 2 trials for CAH in children and polycystic ovary syndrome (PCOS) in women. Additionally, Pamela Wedel has been appointed Vice President of Development Operations, bringing over 30 years of drug development experience.
Spruce Biosciences (NASDAQ: SPRB), a biopharmaceutical company, announced participation in four investor conferences this September. The conferences include H.C. Wainwright Global Investment Conference (Sept 13-14), Baird 2021 Global Healthcare Conference (Sept 14-15), Oppenheimer Fall Healthcare Life Sciences Summit (Sept 20-22), and SVB Leerink CybeRx Series (Sept 22-23). The company is focused on developing therapies for rare endocrine disorders, particularly tildacerfont for classic congenital adrenal hyperplasia and polycystic ovary syndrome.
Spruce Biosciences announces the initiation of its Phase 2 clinical program for tildacerfont in pediatric classic Congenital Adrenal Hyperplasia (CAH) in 2021, with data expected by the first half of 2023. This open-label study will evaluate safety and pharmacokinetics in children aged 6-17 with varying doses. The Phase 3 registrational program is also anticipated to commence in 2023. The company is focused on addressing significant unmet medical needs in rare endocrine disorders, aiming to provide a non-steroidal treatment for classic CAH.
Spruce Biosciences, Inc. (Nasdaq: SPRB) reported Q2 2021 financial results highlighting advancements in its clinical programs. The FDA cleared the IND for tildacerfont for polycystic ovary syndrome (PCOS), enabling a Phase 2 study later this year. A new patent extends exclusivity for tildacerfont until 2038. In clinical trials, tildacerfont showed promising results in reducing ACTH and androstenedione levels in classic congenital adrenal hyperplasia (CAH) patients. The company ended Q2 with $139 million in cash, supporting ongoing development initiatives.
